Patent Grant
8962023
The present invention relates to coatings for medical devices, or films, which are cured, and more particularly to a method of UV curing a coating or stand alone film formed at least in part of a non-polymeric cross-linked gel cured a desired amount, and the resulting structure provided by the curing process.
Coatings and drugs, agents, or compounds are utilized in combination with a number of medical devices, and in particular with implantable medical devices such as stents, stent-grafts, surgical meshes, vascular grafts, and the like. Other devices such as vena cava filters and anastomosis devices may also be used with coatings having drugs, agents, or compounds therein. In addition, surgical medical film is often used in surgical settings, such as in patients undergoing abdominal or pelvic laparotomy as an adjunct intended to reduce the incidence, extent, and severity of postoperative adhesions between different tissues and organs and implantable medical devices such as soft tissue support membranes and mesh.
In general, such coatings and films are manufactured utilizing polymeric based materials. The coatings and films are formed using a number of different manufacturing techniques. However, there has been little progress in the manufacture of coatings or films utilizing non-polymeric based materials in a manner that can form the desired coating or film, with desired degradation properties, while maintaining some of the anti-inflammatory, non-inflammatory, and wound healing properties of some of the non-polymeric substances available.
More specifically, oils are occasionally briefly mentioned as being a potential carrier component for the delivery of a therapeutic from a medical device. However, there has been little development with regard to the determination of how to accomplish the provision of a non-polymeric coating containing a therapeutic, or even a non-polymeric coating maintaining its original anti-inflammatory, non-inflammatory, or wound healing properties. Some of these anti-inflammatory, non-inflammatory, and wound healing characteristics can be found in oils containing fatty acids, especially omega-3 fatty acids, such as fish oil. However, there is little known relating to methods for configuring non-polymeric coatings to carry therapeutic agents in a manner that results in a predefined, desired, rate of degradation to provide for the controlled release of the therapeutic agent or the controlled degradation of the coating.
What is desired is a method of making a non-polymeric biological oil based coating on a medical device or in the form of a stand alone film, which exhibits properties such as anti-adhesion, anti-inflammation, non-inflammation, and enhanced wound healing, to the local tissue that can also be further enhanced with the application of one or more therapeutic agents or medications for absorption into the tissue that is in contact with the coating or film. The method of making directly influences the resulting coating or film and corresponding rate of degradation of the coating or film following implantation, and thus the controlled release of any therapeutic agents contained within. The method of curing also influences the level of inherent anti-inflammation, non-inflammation, and wound healing properties of certain biological oils that is able to be maintained after curing. The present invention is directed toward further solutions to address this need.
Curing with respect to the present invention generally refers to thickening, hardening, or drying of a material brought about by heat, UV, or chemical means.
In accordance with one embodiment of the present invention, a method of curing to form a gel includes providing a non-polymeric substance to be cured. An amount of cross-linking desired within the substance as a result of curing is determined. UV light is applied at a selected intensity for a selected time period based on the determination of amount of cross-linking desired to achieve the desired amount of cross-linking within the substance to form the gel.
In accordance with aspects of the present invention, the substance to be cured can be an oil or oil composition. The substance to be cured can contain fatty acids. The substance to be cured can include at least one therapeutic agent. The agent can be any one or more of antioxidants, anti-inflammatory agents, anti-coagulant agents, drugs to alter lipid metabolism, anti-proliferatives, anti-neoplastics, tissue growth stimulants, functional protein/factor delivery agents, anti-infective agents, imaging agents, anesthetic agents, chemotherapeutic agents, tissue absorption enhancers, anti-adhesion agents, germicides, analgesics, prodrugs, and antiseptics.
In accordance with further aspects of the present invention, the step of determining includes selecting the amount of cross-linking based on a desired rate of degradation of the gel following implantation. The application of UV light/heat occurs at a relatively greater intensity if more cross-linking is desired and at a relatively lesser intensity if a lesser amount of cross-linking is desired. The application of UV light occurs for a relatively greater duration of time if more cross-linking is desired and at a relatively lesser duration of time if a lesser amount of cross-linking is desired. A relatively faster rate of degradation provides for a relatively faster release of therapeutic agent contained within the gel, while a relatively slower rate of degradation provides for a relatively slower and more controlled release of therapeutic agent contained within the gel.
In accordance with further aspects of the present invention, the non-polymeric substance to be cured at least partially includes at least partially cured oil to reduce the amount of time required to achieve the desired amount of cross-linking.
In accordance with further aspects of the present invention, the cross-linked gel is configured to provide controlled release of a therapeutic agent component. The cross-linked gel is bio-absorbable. The cross-linked gel maintains at least one property, such as anti-inflammatory properties, non-inflammatory properties, and wound healing properties.
It should be noted that the term cross-linked gel, as utilized herein with reference to the present invention, refers to a gel that is non-polymeric and is derived from an oil composition comprising molecules covalently cross-linked into a three-dimensional network by one or more of ester, ether, peroxide, and carbon-carbon bonds in a substantially random configuration. In various preferred embodiments, the oil composition comprises a fatty acid molecule, a glyceride, and combinations thereof.
In accordance with further aspects of the present invention, the method can include sterilizing the cross-linked gel with a method of sterilization, such as ethylene oxide, gamma radiation, e-beam, steam, gas plasma, or vaporized hydrogen peroxide (VHP).
In accordance with one embodiment of the present invention, a UV cured non-polymeric gel includes a collection of non-polymeric cross-links resulting from application of UV light/heat at a selected intensity for a selected duration to achieve a desired amount of cross-linking to form the non-polymeric gel.
In accordance with aspects of the present invention, the gel can be derived from an oil or oil composition. The gel can be derived from a substance comprising fatty acids. The gel can include at least one therapeutic agent. The agent can be any one or more of antioxidants, anti-inflammatory agents, anti-coagulant agents, drugs to alter lipid metabolism, anti-proliferatives, anti-neoplastics, tissue growth stimulants, functional protein/factor delivery agents, anti-infective agents, imaging agents, anesthetic agents, chemotherapeutic agents, tissue absorption enhancers, anti-adhesion agents, germicides, analgesics, prodrugs, and antiseptics.
In accordance with further aspects of the present invention, the gel is configured to maintain a desired rate of degradation of the gel following implantation. The gel formed with application of UV light at a relatively higher intensity if more cross-linking is desired and at a relatively lower intensity if a lesser amount of cross-linking is desired. The gel is formed with application of UV light/heat for a relatively greater duration of time if more cross-linking is desired and at a relatively lesser duration of time if a lesser amount of cross-linking is desired.
In accordance with further aspects of the present invention, the gel is formed from at least partially pre-cured oil to reduce the amount of time required to achieve the desired amount of cross-linking. The cross-linked gel is configured to provide controlled release of a therapeutic agent component. The cross-linked gel is bio-absorbable. The cross-linked gel maintains at least one property, such as anti-inflammatory properties, non-inflammatory properties, or wound healing properties.
In accordance with further aspects of the present invention, the gel has been sterilized with a method of sterilization including ethylene oxide, gamma radiation, e-beam, steam, gas plasma, or vaporized hydrogen peroxide (VHP).
In accordance with further aspects of the present invention, the gel is configured as a coating on a medical device or as a stand-alone film. Furthermore, the non-polymeric substance used to form the gel can be pre-treated to increase viscosity prior to curing.
The aforementioned features and advantages, and other features and aspects of the present invention, will become better understood with regard to the following description and accompanying drawings, wherein:
An illustrative embodiment of the present invention relates to the provision of a coating or film that is a cured cross-linked gel and can exhibit anti-inflammatory properties, non-inflammatory properties, anti-adhesion properties, and/or wound healing properties, and corresponding method of making. The cross-linked gel can be its own medical device (i.e., a stand alone film), or the cross-linked gel can be combined with another medical device to provide the desired characteristics, in addition to potentially delivering therapeutic agents. The cross-linked gel is generally formed of a naturally occurring oil, or an oil composition formed in part of a naturally occurring oil having fatty acids. In addition, the oil composition can include a therapeutic agent component, such as a drug or other bioactive agent. The cross-linked gel is implantable in a patient, or applied on the skin surface of the patient, for short term or long term applications, and can include controlled release of the therapeutic agent. As implemented herein, the cross-linked gel is a non-polymeric cross-linked gel derived at least in part from a fatty acid compound.
As utilized herein, the term “bio-absorbable” generally refers to having the property or characteristic of being able to penetrate the tissue of a patient's body. In certain embodiments of the present invention bio-absorption occurs through a lipophilic mechanism. The bio-absorbable substance is soluble in the phospholipid bi-layer of cells of body tissue, and therefore impacts how the bio-absorbable substance penetrates into the cells.
It should be noted that a bio-absorbable substance is different from a biodegradable substance. Biodegradable is generally defined as capable of being decomposed by biological agents, or capable of being broken down by microorganisms or biological processes, in a manner that does not result in cellular uptake of the biodegradable substance. Biodegradation thus relates to the breaking down and distributing of a substance through the patient's body, verses the penetration of the cells of the patient's body tissue. Biodegradable substances, such as polymers, can cause inflammatory response due to either the parent substance or those substances formed during breakdown, and they may or may not be absorbed by tissues. Bio-absorbable substances break down into substances or components that do not cause an inflammatory response and can be consumed by the cells forming the body tissues.
The phrase “controlled release” generally refers to the release of a biologically active agent in a predictable manner over the time period of weeks or months, as desired and predetermined upon formation of the biologically active agent on the medical device from which it is being released. Controlled release includes the provision of an initial burst of release upon implantation, followed by the predictable release over the aforementioned time period.
With regard to the aforementioned oils, it is generally known that the greater the degree of unsaturation in the fatty acids the lower the melting point of a fat, and the longer the hydrocarbon chain the higher the melting point of the fat. A polyunsaturated fat, thus, has a lower melting point, and a saturated fat has a higher melting point. Those fats having a lower melting point are more often oils at room temperature. Those fats having a higher melting point are more often waxes or solids at room temperature. Therefore, a fat having the physical state of a liquid at room temperature is an oil. In general, polyunsaturated fats are liquid oils at room temperature, and saturated fats are waxes or solids at room temperature.
Polyunsaturated fats are one of four basic types of fat derived by the body from food. The other fats include saturated fat, as well as monounsaturated fat and cholesterol. Polyunsaturated fats can be further composed of omega-3 fatty acids and omega-6 fatty acids. Under the convention of naming the unsaturated fatty acid according to the position of its first double bond of carbons, those fatty acids having their first double bond at the third carbon atom from the methyl end of the molecule are referred to as omega-3 fatty acids. Likewise, a first double bond at the sixth carbon atom is called an omega-6 fatty acid. There can be both monounsaturated and polyunsaturated omega fatty acids.
Omega-3 and omega-6 fatty acids are also known as essential fatty acids because they are important for maintaining good health, despite the fact that the human body cannot make them on its own. As such, omega-3 and omega-6 fatty acids must be obtained from external sources, such as food. Omega-3 fatty acids can be further characterized as containing eicosapentaenoic acid (EPA), docosahexanoic acid (DHA), and alpha-linolenic acid (ALA). Both EPA and DHA are known to have anti-inflammatory effects and wound healing effects within the human body.
Oil that is hydrogenated becomes a waxy solid. Attempts have been made to convert the polyunsaturated oils into a wax or solid to allow the oil to adhere to a device for a longer period of time. One such approach is known as hydrogenation, which is a chemical reaction that adds hydrogen atoms to an unsaturated fat (oil) thus saturating it and making it solid at room temperature. This reaction requires a catalyst, such as a heavy metal, and high pressure. The resultant material forms a non-cross-linked semi-solid. Hydrogenation can reduce or eliminate omega-3 fatty acids, and any therapeutic effects (both anti-inflammatory and wound healing) they offer.
For long term controlled release applications, polymers, as previously mentioned, have been utilized in combination with a therapeutic agent. Such a combination provides a platform for the controlled long term release of the therapeutic agent from a medical device. However, polymers have been determined to themselves cause inflammation in body tissue. Therefore, the polymers often must include at least one therapeutic agent that has an anti-inflammatory effect to counter the inflammation caused by the polymer delivery agent. In addition, patients that received a polymer-based implant must also follow a course of long term systemic anti-platelet therapy, on a permanent basis, to offset the thrombogenic properties of the non-absorbable polymer. A significant percentage of patients that receive such implants are required to undergo additional medical procedures, such as surgeries (whether related follow-up surgery or non-related surgery) and are required to stop their anti-platelet therapy. This can lead to a thrombotic event, such as stroke, which can lead to death. Use of the inventive coating described herein can negate the necessity of anti-platelet therapy, and the corresponding related risks described, because there is no thrombogenic polymer reaction to the coating. Other polymer implant patients must follow a course of systemic anti-inflammatory therapy, to offset the inflammatory properties of the non-absorbable polymer. Typical anti-inflammatory agents are immunosupressants and systemic delivery of anti-inflammatory agents can sometimes lead to additional medical complications, such as infection or sepsis, which can lead to long term hospitalization or death. Use of the non-polymeric cross-linked gel of the inventive coating described herein may also negate the necessity of anti-inflammatory therapy, and the corresponding related risks described, because there is no inflammatory reaction to an oil barrier formed in accordance with the present invention.
In addition, some curing methods have been indicated to have detrimental effects on the therapeutic agent combined with the omega-3 fatty acid, making them partially or completely ineffective. As such, oils, and more specifically oils containing omega-3 fatty acids, have been utilized as a delivery agent for the short term uncontrolled release of a therapeutic agent, so that minimal or no curing is required. However, there are no known uses of oils containing omega-3 fatty acids for combination with a therapeutic agent in a controlled release application that makes use of the therapeutic benefits of the omega-3 fatty acids. Further, some application of UV light to the omega-3 fatty acids to cure the oil can lessen the total therapeutic effectiveness of the omega-3 fatty acids, but not eliminate the therapeutic effectiveness. One characteristic that can remain after certain curing by UV methods is the non-inflammatory response of the tissue when exposed to the cured omega-3 fatty acid material. As such, an oil containing omega-3 fatty acids can be exposed to UV light for curing purposes, and still maintain some or even a majority of the therapeutic effectiveness of the omega-3 fatty acids. In addition, although the therapeutic agent combined with the omega-3 fatty acid and cured with the omega-3 fatty acid can be rendered partially ineffective, the portion remaining of the therapeutic agent can, in accordance with the present invention, maintain pharmacological activity and in some cases be more effective than an equivalent quantity of agent delivered with other barrier or coating materials.
It should be noted that as utilized herein to describe the present invention, the terms vitamin E, vitamin E compound, and alpha-tocopherol, are intended to refer to the same or substantially similar substance, such that they are interchangeable and the use of one includes an implicit reference to both. Further included in association with the term vitamin E are such variations including but not limited to one or more of alpha-tocopherol, beta-tocopherol, delta-tocopherol, gamma-tocopherol, alpha-tocotrienol, beta-tocotrienol, delta-tocotrienol, gamma-tocotrienol, alpha-tocopherol acetate, beta-tocopherol acetate, gamma-tocopherol acetate, delta-tocopherol acetate, alpha-tocotrienol acetate, beta-tocotrienol acetate, delta-tocotrienol acetate, gamma-tocotrienol acetate, alpha-tocopherol succinate, beta-tocopherol succinate, gamma-tocopherol succinate, delta-tocopherol succinate, alpha-tocotrienol succinate, beta-tocotrienol succinate, delta-tocotrienol succinate, gamma-tocotrienol succinate, mixed tocopherols, vitamin E TPGS, derivatives, analogs and pharmaceutically acceptable salts thereof.
The cross-linked gel 10 is formed of an oil component. The oil component can be either an oil, or an oil composition. The oil component can be a naturally occurring oil, such as fish oil, cod liver oil, cranberry oil, or other oils having desired characteristics. One example embodiment of the present invention makes use of a fish oil in part because of the high content of omega-3 fatty acids, which provide healing support for damaged tissue, as discussed below. The fish oil also serves as an anti-adhesion agent. In addition, the fish oil maintains anti-inflammatory or non-inflammatory properties as well. The present invention is not limited to formation of the film or gel with fish oil as the naturally occurring oil. However, the following description makes reference to the use of fish oil as one example embodiment. Other naturally occurring oils can be utilized in accordance with the present invention as described herein.
It should be noted that as utilized herein, the term fish oil fatty acid includes but is not limited to omega-3 fatty acid, fish oil fatty acid, free fatty acid, esters of fish oil, triglycerides, or a combination thereof. The fish oil fatty acid includes one or more of arachidic acid, gadoleic acid, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid or derivatives, analogs and pharmaceutically acceptable salts thereof. Furthermore, as utilized herein, the term free fatty acid includes but is not limited to one or more of butyric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, behenic acid, erucic acid, lignoceric acid, analogs and pharmaceutically acceptable salts thereof. The naturally occurring oils, including fish oil, are cured as described herein to form a hydrophobic cross-linked gel, creating the cross-linked gel 10.
It should further be noted that
One aspect of the cross-linked gel 10 mentioned above is that it has anti-adhesion characteristics or properties. By anti-adhesion, what is meant is a characteristic whereby the incidence, extent, and severity of postoperative adhesions, or lacerations or other tissue injuries, between different tissues and organs is reduced. The anti-adhesion characteristic results from the materials used to form the cross-linked gel 10.
More specifically, the cross-linked gel 10 provides a lubricious or anti-adhesive surface against tissue. The cross-linked gel 10 itself, in its substantially cured configuration, can provide a physical anti-adhesion barrier between two sections of tissue, or the cross-linked gel 10 can form an anti-adhesion surface on a medical device, such as the mesh 40. The use of the naturally occurring oil, such as fish oil, provides extra lubrication to the surface of the medical device, which helps to reduce injury. With less injury, there is less of an inflammatory response, and less healing required. The biological oil barrier created by the fatty acid oil derived cross-linked gel likewise provides anti-inflammatory properties and non-inflammatory properties, thus reducing the occurrence of inflammatory response and also adhesions due to inflammation. The oily surface of the cross-linked gel 10 provides the anti-adhesion characteristics. One of ordinary skill in the art will appreciate that different oils will have different anti-adhesive properties, and the oils can be modified to be more liquefied or more solid or waxy, as desired. Accordingly, the degree of anti-adhesive properties offered by the cross-linked gel 10 can vary. The modification of the oils from a more liquid physical state to a more solid, but still flexible, physical state is implemented through the curing process. As the oils are cured, especially in the case of fatty acid-based oils such as fish oil, cross-links form creating a gel. As the curing process is performed over increasing time durations and/or increasing temperature or UV light exposure conditions, more cross-links form transitioning the gel from a relatively liquid gel to a relatively solid-like, but still flexible, gel structure.
Another aspect of the present invention is that the cross-linked gel 10 is formed of the bio-absorbable material, such as naturally occurring fish oil, in accordance with the example embodiment described herein. The bio-absorbable properties of the naturally occurring oil enable the cross-linked gel 10 to be absorbed by the cells of the body tissue (i.e., bio-absorbable). In example embodiments of the present invention, the bio-absorbable cross-linked gel contains lipids, many of which originate as triglycerides. It has previously been demonstrated that triglyceride byproducts, such as partially hydrolyzed triglycerides and fatty acid molecules can integrate into cellular membranes and enhance the solubility of drugs into the cell. Whole triglycerides are known not to enhance cellular uptake as well as partially hydrolyzed triglyceride, because it is difficult for whole triglycerides to cross cell membranes due to their relatively larger molecular size. Vitamin E compounds can also integrate into cellular membranes resulting in decreased membrane fluidity and cellular uptake.
Compounds that move too rapidly through a tissue may not be effective in providing a sufficiently concentrated dose in a region of interest. Conversely, compounds that do not migrate in a tissue may never reach the region of interest. Cellular uptake enhancers such as fatty acids and cellular uptake inhibitors such as alpha-tocopherol can be used alone or in combination to provide an effective transport of a given compound to a given region or location. Both fatty acids and alpha-tocopherol are accommodated by the cross-linked gel of the present invention described herein. Accordingly, fatty acids and alpha-tocopherol can be combined in differing amounts and ratios to contribute to a cross-linked gel in a manner that provides control over the cellular uptake characteristics of the cross-linked gel and any therapeutic agents mixed therein.
For example, the amount of alpha-tocopherol can be varied in the cross-linked gel. Alpha-tocopherol (vitamin E compound) is known to slow autoxidation in fish oil by reducing hydroperoxide formation, which results in a decrease in the amount of cross-linking in cured fish oil. It has been shown that even with fewer cross-links, the addition of varying amounts of alpha-tocopherol can be used to increase the time in which the cross-linked gel degrades compared to a cross-linked gel of fish oil alone. The addition of alpha-tocopherol to the oil or oil composition prior to forming the cross-linked gel can result in fewer cross-links when compared with the oil without alpha-tocopherol. Although there are fewer cross-links, the degradation period is extended with the alpha-tocopherol added. In addition alpha-tocopherol can be used to increase solubility of drugs in the fish oil forming the cross-linked gel. Thus, varying the amount of alpha-tocopherol present in the cross-linked gel can impact the resulting formation. Alpha-tocopherol can actually protect the therapeutic drug during curing, which increases the resulting drug load in the cross-linked gel after curing. Furthermore, with certain therapeutic drugs, the increase of alpha-tocopherol in the cross-linked gel serves to slow and extend drug release due to the increased solubility of the drug in the alpha-tocopherol component of the cross-linked gel. This reflects the cellular uptake inhibitor functionality of alpha-tocopherol, in that the uptake of the drug is slowed and extended over time.
It should further be emphasized that the bio-absorbable nature of the cross-linked gel results in the cross-linked gel 10 being completely absorbed over time by the cells of the body tissue. There are no substances in the cross-linked gel, or break down products of the cross-linked gel, that induce an inflammatory response. The cross-linked gel 10 is generally composed of, or derived from, omega-3 fatty acids bound to triglycerides, potentially also including a mixture of free fatty acids and vitamin E compounds (alpha-tocopherol). The triglycerides are broken down by lipases (enzymes) which result in free fatty acids that can than be transported across cell membranes. Subsequently, fatty acid metabolism by the cell occurs to metabolize any substances originating with the cross-linked gel. The bio-absorbable nature of the cross-linked gel of the present invention results in the cross-linked gel being absorbed over time, leaving only an underlying delivery or other medical device structure that is biocompatible. There is no foreign body inflammatory response to the bio-absorbable cross-linked gel.
Although the present invention is bio-absorbable to the extent that the cross-linked gel 10 experiences the uptake into or through body tissues, in the specific embodiment described herein formed using naturally occurring oils, the exemplar oils are also lipid based oils. The lipid content of the oils provides a highly bio-absorbable cross-linked gel 10. More specifically, there is a phospholipids layer in each cell of the body tissue. The fish oil, and equivalent oils, contain lipids as well. There is a lipophilic action that results where the lipids are attracted by each other in an effort to escape the aqueous environment surrounding the lipids.
A further aspect of the cross-linked gel 10 is that the specific type of oil can be varied, and can contain elements beneficial to healing. The cross-linked gel also provides a natural scaffold for cellular growth and remodeling with clinical applications in general surgery, spinal repair, orthopedic surgeries, tendon and ligament repairs, gynecological and pelvic surgeries, and nerve repair applications. The addition of therapeutic agents to the cross-linked gels used in these applications can be utilized for additional beneficial effects, such as pain relief or infection minimization. In addition, non-surgical applications include external wound care, such as a treatment for burns or skin ulcers, without therapeutics as a clean, non-permeable, non-adhesive, anti-inflammatory, non-inflammatory dressing, or with added therapeutics for additional beneficial effects. The cross-linked gel may also be used as a transdermal drug delivery patch.
The process of wound healing involves tissue repair in response to injury and it encompasses many different biologic processes, including epithelial growth and differentiation, fibrous tissue production and function, angiogenesis, and inflammation. The inventive cross-linked gel has been shown in an animal model not to produce an inflammatory response, but still provide excellent cellular overgrowth with little to no fibrous capsule formation. Accordingly, the cross-linked gel provides an excellent material suitable for wound healing applications.
Another aspect of the cross-linked gel 10 mentioned above is that the cross-linked gel 10 can contain therapeutic agents for delivery to the body tissue. Therapeutic agents have been delivered to a targeted location in a human utilizing a number of different methods in the past. For example, agents may be delivered nasally, transdermally, intravenously, orally, or via other conventional methods. Delivery may vary by release rate (i.e., quick release or slow release). Delivery may also vary as to how the drug is administered. Specifically, a drug may be administered locally to a targeted area, or administered systemically.
As utilized herein, the phrase “therapeutic agent(s)” refers to a number of different drugs or agents available, as well as future agents that may be beneficial for use with the cross-linked gel of the present invention. Therapeutic agents can be added to the cross-linked gel 10, and/or the medical device in combination with the cross-linked gel 10 as discussed herein. The therapeutic agent component can take a number of different forms including anti-oxidants, anti-inflammatory agents, anti-coagulant agents, drugs to alter lipid metabolism, anti-proliferatives, anti-neoplastics, tissue growth stimulants, functional protein/factor delivery agents, anti-infective agents, anti-imaging agents, anesthetic agents, therapeutic agents, tissue absorption enhancers, anti-adhesion agents, germicides, antiseptics, analgesics, prodrugs, and any additional desired therapeutic agents such as those listed in Table 1 below.
Some specific examples of therapeutic agents useful in the anti-restenosis realm include cerivastatin, cilostazol, fluvastatin, lovastatin, paclitaxel, pravastatin, rapamycin, a rapamycin carbohydrate derivative (for example, as described in US Patent Application Publication 2004/0235762), a rapamycin derivative (for example, as described in U.S. Pat. No. 6,200,985), everolimus, seco-rapamycin, seco-everolimus, and simvastatin. With systemic administration, the therapeutic agent is administered orally or intravenously to be systemically processed by the patient. However, there are drawbacks to a systemic delivery of a therapeutic agent, one of which is that the therapeutic agent travels to all portions of the patient's body and can have undesired effects at areas not targeted for treatment by the therapeutic agent. Furthermore, large doses of the therapeutic agent only amplify the undesired effects at non-target areas. As a result, the amount of therapeutic agent that results in application to a specific targeted location in a patient may have to be reduced when administered systemically to reduce complications from toxicity resulting from a higher dosage of the therapeutic agent.
Accordingly, an alternative to the systemic administration of a therapeutic agent is the use of a targeted local therapeutic agent delivery approach. With local delivery of a therapeutic agent, the therapeutic agent is administered using a medical device or apparatus, directly by hand, or sprayed on the tissue, at a selected targeted tissue location of the patient that requires treatment. The therapeutic agent emits, or is otherwise delivered, from the medical device apparatus, and/or carrier, and is applied to the targeted tissue location. The local delivery of a therapeutic agent enables a more concentrated and higher quantity of therapeutic agent to be delivered directly at the targeted tissue location, without having broader systemic side effects. With local delivery, the therapeutic agent that escapes the targeted tissue location dilutes as it travels to the remainder of the patient's body, substantially reducing or eliminating systemic side effects.
Targeted local therapeutic agent delivery using a medical device can be further broken into two categories, namely, short term and long term ranging generally within a matter of seconds or minutes to a few days or weeks to a number of months. Typically, to achieve the long term delivery of a therapeutic agent, the therapeutic agent must be combined with a delivery agent, or otherwise formed with a physical impediment as a part of the medical device, to slow the release of the therapeutic agent.
Prior attempts to create films and drug delivery platforms, such as in the field of stents, primarily make use of high molecular weight synthetic polymer based materials to provide the ability to better control the release of the therapeutic agent. Essentially, the polymer in the platform releases the drug or agent at a predetermined rate once implanted at a location within the patient. Regardless of how much of the therapeutic agent would be most beneficial to the damaged tissue, the polymer releases the therapeutic agent based on properties of the polymer. Accordingly, the effect of the therapeutic agent is substantially local at the surface of the tissue making contact with the medical device having the coating. In some instances the effect of the therapeutic agent is further localized to the specific locations of, for example, stent struts pressed against the tissue location being treated. These prior approaches can create the potential for a localized toxic effect.
The cross-linked gel 10 of the present invention, however, makes use of the natural oils to form a non-polymeric natural oil based therapeutic agent delivery platform, if desired. Furthermore, the cross-linked gel 10 can be formed in a manner that creates the potential for controlled long term release of a therapeutic agent, while still maintaining the benefits of the natural oil component of the cross-linked gel 10.
More specifically, it is known that oil that is oxygenated becomes a waxy solid. Attempts have been made to convert the polyunsaturated oils into a wax or solid to allow the oil to adhere to a device for a longer period of time. One such approach applies the oil to the medical device and allows the oil to dry.
With the present invention, and in the field of soft tissue applications, and in part because of the lipophilic mechanism enabled by the bio-absorbable lipid based cross-linked gel 10 of the present invention, the uptake of the therapeutic agent is facilitated by the delivery of the therapeutic agent to the cell membrane by the bio-absorbable cross-linked gel 10. Further, the therapeutic agent is not freely released into the body fluids, but rather, is delivered directly to the cells and tissue. In prior configurations using polymer based coatings, the drugs were released at a rate regardless of the reaction or need for the drug on the part of the cells receiving the drug.
In addition, when the oil provided to form the cross-linked gel 10 is a naturally occurring oil containing the omega-3 fatty acids (including DHA and EPA), the process for forming the cross-linked gel 10 can be tailored to avoid causing detrimental effects to the beneficial properties of the omega-3 fatty acids, or at least effects too detrimental to have any lasting effect. As described herein, certain properties of the fatty acids may lose their effectiveness, however other desired properties are maintained. If there is no concern for maintaining the beneficial effects, the curing and other steps leading to the formation of the cross-linked gel 10 can include steps that may reduce some of the beneficial properties of the omega-3 fatty acids, as understood by one of ordinary skill in the art. Example embodiments illustrating the formation and different configurations of the cross-linked gel 10 are provided herein.
The cross-linked gel 10 of the present invention serves as a non-polymeric biological oil based cross-linked gel and can also serve as a physical cross-linked gel if sufficiently cured. In accordance with the example embodiments described herein, the cross-linked gel is formed of a non-polymeric cross-linked gel derived from fatty acid compounds. The fatty acid compounds include omega-3 fatty acids when the oil utilized to form the cross-linked gel is fish oil or an analog or derivative thereof. As liquid fish oil is heated, autoxidation occurs with the absorption of oxygen into the fish oil to create hydroperoxides in an amount dependent upon the amount of unsaturated (C═C) sites in the fish oil. However, the (C═C) bonds are not consumed in the initial reaction. Concurrent with the formation of hydroperoxides is the isomerization of (C═C) double bonds from cis to trans in addition to double bond conjugation. It has been demonstrated that hydroperoxide formation increases with temperature. Heating of the fish oil allows for cross-linking between the fish oil unsaturated chains using a combination of peroxide (C—O—O—C), ether (C—O—C), and hydrocarbon (C—C) bridges. The formation of the cross-links results in gelation of the cross-linked gel after the (C═C) bonds have substantially isomerized into the trans configuration. The (C═C) bonds can also form C—C cross-linking bridges in the glyceride hydrocarbon chains using a Diels-Alder Reaction. In addition to solidifying the cross-linked gel through cross-linking, both the hydroperoxide and (C═C) bonds can undergo secondary reactions converting them into lower molecular weight secondary oxidation byproducts including aldehydes, ketones, alcohols, fatty acids, esters, lactones, ethers, and hydrocarbons.
The non-polymeric cross-linked gel derived from fatty acid compounds, such as those of fish oil, includes a cross-linked structure of triglyceride and fatty acid molecules in addition to free and bound glycerol, monoglyceride, diglyceride, and triglyceride, fatty acid, anhydride, lactone, aliphatic peroxide, aldehyde, and ketone molecules. There are a substantial amount of ester bonds remaining after curing in addition to peroxide linkages forming the majority of the cross-links in the gel. The cross-linked gel degrades into fatty acid, short and long chain alcohol, and glyceride molecules, which are all non-inflammatory and likewise consumable by cells in the soft tissue to which the cross-linked gel is applied. Thus, the cross-linked gel is bio-absorbable.
UV initiated curing (photo-oxygenation) in accordance with the present invention involves the interaction between a double bond and singlet oxygen produced from ordinary triplet oxygen by light and typically in the presence of a sensitizer such as chlorophyll or methylene blue and results in the formation of hydroperoxides. The chemical reaction is described in the following graphic.
Since the above described reaction is not a radical chain process, it possess no induction period and is typically unaffected by antioxidants commonly used to inhibit autoxidation. However, this reaction can be inhibited by single oxygen quenchers such as carotene. This reaction is limited to C═C carbon atoms and results in a conversion from cis to trans C═C isomers during curing (as occurs with heat initiated curing). However, photo-oxygenation using UV is a relatively quicker reaction than autoxidation from heat curing, in the realm of about 1000-1500 times faster. The quicker reaction especially holds true for methylene interrupted polyunsaturated fatty acids, such as EPA and DHA, which are found in the fish oil based embodiments of the present invention.
An important aspect of UV curing when compared to heat curing is that although the byproducts obtained by both curing methods are similar, they are not necessarily identical in amount or chemical structure. One reason for this is due to the ability of photo-oxygenation to create hydroperoxides at more possible C═C sites as shown for linolenate in the below graphic.
Photo-oxygenation, such as that which results from UV curing, due to its enhanced ability to create inner hydroperoxides, also results in the ability to form relatively greater amounts of cyclic byproducts, which also relates to peroxide cross-linking between fish oil hydrocarbon chains. For example, photo-oxygenation of linolenate results in 6 different types of hydroperoxides to be formed where autoxidation results in only 4. The greater amount of hydroperoxides created using photo-oxygenation results in a similar, but slightly different, structure and amount of secondary byproducts to be formed relative to autoxidation from heat curing. Specifically, these byproducts are aldehydes, ketones, alcohols, fatty acids, esters, lactones, ethers, and hydrocarbons.
An oil component is applied to the surface on top of the release agent (step 102). As noted previously, the oil component can be a naturally occurring oil, such as fish oil, cod liver oil, cranberry oil, or other oils having desired characteristics. In addition, the oil component can be an oil composition, meaning a composition containing oil in addition to other substances. For example, the oil composition can be formed of the oil component in addition to a solvent and/or a preservative. Solvents can include a number of different alternatives, including ethanol or N-Methyl-2-Pyrrolidone (NMP). The preservative can also include a number of different alternatives, including vitamin E compounds. One of ordinary skill in the art will appreciate that there are a number of different solvents and preservatives available for use with the oil component to form the oil composition, and as such the present invention is not limited to only those listed in the examples herein. The solvent can be useful to alter the physical properties of the oil, as well as prepare the oil for combination with a therapeutic agent as described below. The preservative can also be useful in altering the physical properties of the oil component, as well as protecting some of the beneficial properties of the oil component during certain curing processes. Such beneficial properties include the healing and anti-inflammatory characteristics previously mentioned.
The oil component can be combined with one or more therapeutic agents to form an oil composition. Thus, if the added therapeutic benefit of a particular therapeutic agent or agents is desired, the therapeutic agent(s) can be added to the oil component prior to application to the surface, along with the oil component during application to the surface (including mixing with the oil component prior to application), or after the oil component has been applied (step 104). The different alternatives for adding the therapeutic agent(s) are determined in part based on the desired effect and in part on the particular therapeutic agent(s) being added. Some therapeutic agents may have reduced effect if present during a subsequent curing step. Some therapeutic agents may be more useful intermixed with the oil component to extend the release period, or applied to the surface of the oil component, resulting in a faster release because of increased exposure. One of ordinary skill in the art will appreciate that a number of different factors, such as those listed above in addition to others, can influence when in the process the therapeutic agent is added to the oil component, or the cross-linked gel 10. Accordingly, the present invention is not limited to the specific combinations described, but is intended to anticipate all such possible variations for adding the therapeutic agent(s).
For example, if 80% of a therapeutic agent is rendered ineffective during curing, the remaining 20% of therapeutic agent, combined with and delivered by the barrier can be efficacious in treating a medical disorder, and in some cases have a relatively greater therapeutic effect than the same quantity of agent delivered with a polymeric or other type of coating or barrier. This result can be modified with the variance of alpha-tocopherol to protect the therapeutic agent during the curing process, and then slow and extend the delivery of the therapeutic agent during absorption of the barrier layer into the tissue.
The oil component (or composition if mixed with other substances) is then hardened into the cross-linked gel 10 (step 106). The step of hardening can include hardening, or curing, such as by introduction of UV light, heat, oxygen or other reactive gases, chemical curing, or other curing or hardening method. The purpose of the hardening or curing is to transform the more liquid consistency of the oil component or oil composition into a more solid film or gel, while still maintaining sufficient flexibility to allow bending and wrapping of the film or gel as desired. However, the hardening process as described herein does not refer to or include the process of hydrogenation.
After the cross-linked gel 10 has formed, another determination is made as to whether therapeutic agents should be applied to the gel. If desired, the therapeutic agent(s) is added to the cross-linked gel 10 (step 108). Subsequently, the cross-linked gel 10 is removed from the surface (step 110). Once again, there is opportunity to apply a therapeutic agent(s) to the cross-linked gel 10 on one or both sides of the cross-linked gel 10. If such therapeutic agent(s) is desired, the therapeutic agent(s) is applied (step 112). The additional therapeutic agent can also be applied in the form of a non-cured or minimally cured oil, such as fish oil. The oil can likewise include other therapeutic agents mixed therewith. The resulting structure of such an application forms the underlying cross-linked gel 10 that is cured to form the gel, with a top coating of oil and potentially additional therapeutic agent layered on top. This structure enables the provision of a short term release of therapeutic from the oil top layer combined with a longer term release from the cured gel, which takes more time to degrade.
After application of the therapeutic agent(s), or after the cross-linked gel 10 is removed from the surface, the cross-linked gel 10 is sterilized. The sterilization process can be implemented in a number of different ways. For example, sterilization can be implemented utilizing ethylene oxide, gamma radiation, E beam, gas plasma, or vaporized hydrogen peroxide (VHP). One of ordinary skill in the art will appreciate that other sterilization processes can also be applied, and that those listed herein are merely examples of sterilization processes that result in a sterilization of the cross-linked gel 10, preferably without having a detrimental effect on the cross-linked gel.
It should be noted that the oil component or oil composition can be added multiple times to create multiple tiers in forming the cross-linked gel 10. For example, if a thicker cross-linked gel 10 is desired, additional tiers of the oil component or oil composition can be added after steps 100, 104, 106, 108, 110, or 112. Different variations relating to when the oil is hardened and when other substances are added to the oil are possible in a number of different process configurations. Accordingly, the present invention is not limited to the specific sequence illustrated. Rather, different combinations of the basic steps illustrated are anticipated by the present invention.
As understood by one of ordinary skill in the art, the properties of the mesh 40 and the cross-linked gel 10 can vary. There may be a requirement for the mesh 40 to have one side, or a portion of a side, that has anti-adhesion properties for a period of several days. Alternatively, multiple sides of the mesh 40 may be required to have anti-adhesion properties. As such, the cross-linked gel 10 can be applied to all sides, or portions of sides, or portions of one side of the mesh 40.
In addition, the requirement may be for the anti-adhesion properties to last several weeks, or even longer. Accordingly, the rate of degradation can also be varied by changing such properties as amount of cross-linking, thickness, and existence of additives, such as vitamin E compounds to achieve longer or shorter term anti-adhesion properties. In addition, there may be a desire to include a therapeutic agent to reduce inflammation, provide antibiotic therapy, or other therapeutic measures, in combination with the use of the mesh 40. Accordingly, the therapeutic agent(s) can be added to the cross-linked gel 10 to achieve the desired controlled release of the therapeutic agent after implantation. As previously described, combinations of cured oils top coated with lesser cured or non-cured oils and therapeutic agents can form the cross-linked gel 10.
The particular properties or characteristics of the mesh 40 are determined based on the desired use of the mesh 40. A common implementation is for the mesh 40 to be formed of a bio-compatible material, such as polypropylene, however other bio-compatible materials can be utilized, such as a mesh formed of the same or similar substance as the cross-linked gel 10 (i.e., oil based).
A determination is made as to whether a release agent should be added to the medical device to aid in removing the device from its location (e.g., on a surface) after combination with the cross-linked gel 10. If a release agent is required, the release agent is applied to the medical device (step 152). An example release agent for such an application is polyvinyl alcohol.
The medical device is then combined with the cross-linked gel 10 (step 154). Depending on the particular medical device, the combination with the cross-linked gel 10 can be implemented more efficiently by either applying the cross-linked gel 10 to the medical device, or placing the medical device on the cross-linked gel 10. For example, in the case of the mesh 40, the mesh 40 can be placed on top of the cross-linked gel 10, or the cross-linked gel 10 can be placed on top of the mesh 40.
The medical device and the cross-linked gel are then cured to create a bond (step 156). The curing process can be one of several known processes, including but not limited to applying heat, or UV light, or chemical curing, to cure the cross-linked gel. After curing, if there is any release agent present, the release agent is washed away using water, or some other washing agent (step 158).
As with the method of
Furthermore, the formation of the oil composition can be done in accordance with different alternatives to the methods described. For example, prior to forming the cross-linked gel 10, a preservative, such as Vitamin E compounds can be mixed with the naturally occurring oil component to form the oil composition. A solvent can be mixed with a therapeutic agent, and then added to the naturally occurring oil to form the oil composition. The solvent can be chosen from a number of different alternatives, including ethanol or N-Methyl-2-Pyrrolidone (NMP). The solvent can later be removed with vacuum or heat. Other solvent alternatives can include, but are not limited to, a solvent or mixture of solvents including solvents that are generally acceptable for pharmaceutical use. Suitable solvents include, for example: alcohols and polyols, such as C2-C6 alkanols, 2-ethoxyethanol, ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediols and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, and polypropylene glycol; amides, such as 2-pyrrolidone, 2-piperidone, 2-caprolactam, N-alkylpyrrolidone, N-methyl-2-pyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam, dimethylacetamide; esters, such as ethyl acetate, methyl acetate, butyl acetate, ethylene glycol diethyl ether, ethylene glycol dimethyl ether, propylene glycol dimethyl ether, ethyl proprionate, tributylcitrate, acetyl triethylcitrate, acetyl tributyl citrate, triethylcitrate, ethyl oleate, ethyl caprylate, ethyl cutyrate, tracetin, ε-caprolactone and isomers thereof, δ-valerolactorne and isomers thereof, β-butyrolactone and isomers thereof; and other solvents, such as water, dimethylsulfoxide, benzyl benzoate, ethyl lactate, acetone, methylethyl ketone, dimethylsolfone, tetrahydrofuran, decylmethylsufoxide, N,N-diethyl-m-toulamide or 1-dodecylazacycloheptan-2-one, hexane, chloroform, dichloromethane.
In addition, it should again be noted that the oil component or oil composition can be added multiple times to create multiple tiers in forming the cross-linked gel 10. If a thicker cross-linked gel 10 is desired, additional tiers of the oil component or oil composition can be added after steps 174 and 176. Different variations relating to when the oil is hardened and when other substances are added to the oil are possible in a number of different process configurations. Accordingly, the present invention is not limited to the specific sequence illustrated. Rather, different combinations of the basic steps illustrated are anticipated by the present invention.
Depending on the type of therapeutic agent component, the resulting cross-linked gel 10 can maintain its bio-absorbable characteristics if the therapeutic agent component is also bio-absorbable.
The therapeutic agent component, as described herein, has some form of therapeutic or biological effect. The oil component or oil composition component can also have a therapeutic or biological effect. Specifically, the cross-linked gel 10 (and its oil constituents) enable the cells of body tissue of a patient to absorb the cross-linked gel 10 itself, rather than breaking down the gel and disbursing by-products of the gel for ultimate elimination by the patient's body.
As previously stated, and in accordance with embodiments of the present invention, the cross-linked gel 10 is formed of a naturally occurring oil, or composition including a naturally occurring oil, such as fish oil, cod liver oil, cranberry oil, and the like. A characteristic of the naturally occurring oil is that the oil includes lipids, which contributes to the lipophilic action described later herein, that is helpful in the delivery of therapeutic agents to the cells of the body tissue. In addition, the naturally occurring oil can include the essential omega-3 fatty acids in accordance with several embodiments of the present invention.
It should also be noted that the present description makes use of the mesh 40 as an example of a medical device that can be combined with the cross-linked gel 10 of the present invention. However, the present invention is not limited to use with the mesh 40. Instead, any number of other implantable medical devices can be combined with the cross-linked gel 10 in accordance with the teachings of the present invention. Such medical devices include catheters, grafts, balloons, prostheses, stents, other medical device implants, and the like. Furthermore, implantation refers to both temporarily implantable medical devices, as well as permanently implantable medical devices.
Returning to the step of curing as described herein, the step can have a number of different variations and permutations that ultimately influence the properties of the resulting cured cross-linked gel, and any therapeutic agents if include therein. In this instance making use of a naturally occurring oil, such as fish oil, such oils or oil compositions as described herein can be heated to increase viscosity. The level of UV light and the time duration of exposure of the oil or oil composition will affect how viscous the oil or oil composition becomes.
In addition, combining pre-cured, highly viscous oil with untreated oil results in a faster cure time of the resulting combination when forming the cross-linked gel. Also, taking a pre-cured oil and decreasing its viscosity slightly with solvent will result in a faster cure time as well. To demonstrate the effectiveness of a combination of UV and heat from UV curing relative to exclusive heat curing, the following example is provided.
UV light was utilized to initiate curing in fish oil. No sensitizer was added to the fish oil during UV curing. In addition, the UV lamps used were of relatively low power (15W at 252 nm) and reached a temperature of 88-90° F. during curing. Thus, the films cured using the UV process described here were cured using a combination of photo-oxygenation and autoxidation initiation pathways. Also, since no sensitizer was added directly to the fish oil to create the singlet oxygen needed to cure the fish oil, the kinetics of the process are similar, but at a lower efficiency.
An FTIR spectrum analysis for heat and UV-heat cured fish oil coatings encapsulating polypropylene mesh was performed. The heat cured mesh coating was created by heating the coating at 200° F. for 48 hours in a high airflow oven. The UV-heat cured mesh coating was created by curing for 29 hours with the “rough side” of the mesh facing up toward the UV lamp (15 W at 252 nm, temperature of chamber 88-90° F.), followed by flipping the mesh over for an additional 19 hours, with a total curing time of 48 hours. There was no high airflow used in the UV-air curing experiment.
The resulting cured coatings had several differences. The trans C═C bonds were almost completely consumed using the UV-heat curing method; whereas they were still present using heat curing alone. In addition, the UV-heat curing spectrum possess more OH bands (indicative of alcohol and fatty acid byproduct formation), less CH2 band intensity, greater anhydride/aliphatic peroxide/lactone cross-linking, and more fatty acid/ketone C═O absorption, relative to the purely heat cured coating. Also, similar to the heat cured fish oil coating, a majority of the ester bonds of the fish oil triglyceride headgroup are retained using the UV-heat curing method.
The coating of the UV-heat curing method contains a greater amount of oxidized byproducts than the coating of the heat cured method, as evidenced by greater OH (alcohol and fatty acid) and fatty acid/ketone C═O bands. In addition, due to the increase in hydroperoxide formation due to photo-oxygenation chemistry, there is a greater amount of anhydride/aliphatic peroxide/lactone cross-linking absorption. Furthermore, there are a greater amount of carbon-carbon cross-linking, and the UV-heat cured mesh coating contains shorter hydrocarbon chain lengths than the heat cured method.
As evidenced by the examples herein, by using UV light in addition to heat, the fish oil curing chemistry can differ in the resulting coatings prepared over a similar time frame. Specifically, the UV-heat cured coating possesses greater amounts of oxidized byproducts, greater amounts of cross-linking, and shorter hydrocarbon chain segments. Ultimately, the resulting coating having been cured by UV-heat degrades in a manner that releases drugs contained therein in a similar but different manner to the heat cured coatings. The below examples illustrate this relationship.
A fish oil and CSA encapsulated mesh was manufactured using UV lamps (15 watts, at 88-90° F.) for 48 hours, using 125 ul of formulation per 1×1″ sample. Some “pin holes” were observed in the coating. The formulation was 2.85% CSA in Fish Oil with no solvent, but with heating at 37° C. for 1 hour with vortexing. An average amount extracted after curing (as measured by HPLC) was 265 micrograms. Based on coating weight, this represents an 8% CSA survival rate. The graph of
A coated mesh was manufactured with a formulation of 2.84% Cyclosporine in Fish Oil. No solvent was used, and Cyclosporine was soluble in the fish oil with slight heating at 37° C. One coating was heated for 3 days at 150° F. and a second coating was heated for 24 hours at 200° F. After curing, drug loading was about 478 ug (14.22% recovery) for the 200° F. cured mesh and about 1158 ug (26.00% recovery) for the 150° F. cured mesh. The coatings were then degraded and the drug release measured as illustrated in the graph of
Based on the measured results of the above two examples of curing, the first being two variations of heat curing and the second being a variation of UV curing, the graph of
The graph of
A coated mesh (mesh structure encapsulated in the coating) was manufactured and cured using UV lamps (15 watts, at 88-90° F.) for 48 hours. An amount of 125 ul of formulation was used per 1×1″ sample. Some “pin holes” were observed in the coating. The formulation was about 4.58% Rapamycin in Fish Oil (where the percentage was based on no remaining nMP in formulation, where any trace amounts should be removed after curing). An average amount of drug was extracted based on HPLC analysis in the amount of about 611 micrograms. Based on coating weight, this represents an 18% Rapamycin survival rate. The degradation and drug release is depicted in the graph of
A formulation of about 4.88% Rapamycin (after solvent removal) in fish oil was provided in the coating. The coating was cured by heating for 3 days at 150° F. Initial drug loading measured after curing using HPLC was about 378 ug. The coating was degraded and drug release measured as depicted in the graph of
Based on the measured results of the above two examples of curing, the first being two UV-heat curing and the second being a variation of heat curing, the graph of
These results demonstrate that UV-cured fish oil coatings may result in a faster dissolution than 150° F. heat-cured coatings when loading Rapamycin in the coating.
In view of the above examples, the previously described methods of manufacture that include a curing step can be implemented using a UV-heat curing approach. In accordance with the method of the present invention, the curing process (such as referred to in step 156 in
In general, a higher UV light intensity will result in a greater number of cross-links than a lower UV light intensity. Furthermore, in general, a relatively longer duration of cure time will result in a greater number of cross-links than a relatively shorter duration of cure time.
Modifying the starting pre-cured viscosity or pre-cured oil concentration in the mixture will enhance the curing speed. One of ordinary skill in the art will appreciate that the scope of the present invention is not limited to only coating on the mesh, but rather has application to other medical devices, or as a stand-alone film.
The curing conditions utilized, such as the duration of time and the intensity of UV light can influence the amount of cross-linking that occurs in the cross-linked gel (i.e., the cross-link density). Cured fish oil coatings enable regulation of the release profile of drug-loaded oil-based coatings from implantable devices. The release profile can be controlled through changes in oil coating chemistry by varying coating composition, UV light intensity, and cure times. The position of the drug-containing layer on the coated device provides an additional mechanism to alter the release profile of the drug-loaded fish oil coating. This can be achieved by either loading the drug into the encapsulating base layer of the device, or by coating a topcoat overlayer coating onto the previously cured encapsulating base layer.
More specifically, curing conditions utilized to form the cross-links, such as time and intensity can influence the amount of coating cross-linking density and byproduct formation, which in turn effects the coating degradation. Thus, by altering the curing conditions employed, the dissolution rate of the therapeutic compound of interest is also altered.
Furthermore, the oil component itself, in the form of fish oil for example, can provide therapeutic benefits in the form of reduced inflammation, and improved healing, if the fish oil composition is not substantially modified during the process that takes the naturally occurring fish oil and forms it into the cross-linked gel 10. Some prior attempts to use natural oils as coatings have involved mixing the oil with a solvent, or curing the oil in a manner that destroys the beneficial aspects of the oil. The solvent utilized in the example cross-linked gel 10 embodiment of the present invention (NMP) does not have such detrimental effects on the therapeutic properties of the fish oil. Thus the benefits of the omega-3 fatty acids, and the EPA and DHA substances are substantially preserved in the cross-linked gel of the present invention.
Therefore, the cross-linked gel 10 of the present invention includes the bio-absorbable naturally occurring oil (i.e., fish oil). The cross-linked gel 10 is thus able to be absorbed by the cells of the body tissue. With the present invention, because of the lipophilic action enabled by the bio-absorbable lipid based cross-linked gel 10 of the present invention, the intake by the tissue cells of the cross-linked gel 10, and any therapeutic agent component, is substantially controlled by the cells themselves. In configurations using polymer based materials, the drugs were released at a rate regardless of the reaction or need for the drug on the part of the cells receiving the drug. With the cross-linked gel 10 of the present invention, the cells can intake as much of the cross-linked gel 10, and correspondingly the therapeutic agent, as is needed by the damaged cell requiring treatment.
In addition, the bio-absorbable nature of the cross-linked gel 10 results in the cross-linked gel 10 being completely absorbed over time by the cells of the body tissue. There is no break down of the cross-linked gel 10 into sub parts and substances that are inflammatory and are eventually distributed throughout the body and in some instances disposed of by the body, as is the case with biodegradable synthetic polymer coatings. The bio-absorbable nature of the cross-linked gel 10 of the present invention results in the cross-linked gel 10 being absorbed, leaving only the medical device structure, if the cross-linked gel 10 is not implanted alone. There is no foreign body inflammatory response to the cross-linked gel 10.
In addition, the cross-linked gel 10 provides a lubricious or anti-adhesive surface against tissue. The cross-linked gel 10 itself can provide an anti-adhesion barrier between two sections of tissue, or the cross-linked gel 10 can form an anti-adhesion surface on a medical device, such as the mesh 40. The use of the naturally occurring oil, such as fish oil, provides extra lubrication to the surface of the medical device, which helps to reduces injury. With less injury, there is less of an inflammatory response, and less healing required. Likewise the fatty acid derived cross-linked gel that makes up the cross-linked gel maintains anti-inflammatory properties and non-inflammatory properties, which also substantially lowers the inflammatory response of the tissue. The reduced inflammation also reduces adhesions.
Numerous modifications and alternative embodiments of the present invention will be apparent to those skilled in the art in view of the foregoing description. Accordingly, this description is to be construed as illustrative only and is for the purpose of teaching those skilled in the art the best mode for carrying out the present invention. Details of the structure may vary substantially without departing from the spirit of the invention, and exclusive use of all modifications that come within the scope of the appended claims is reserved. It is intended that the present invention be limited only to the extent required by the appended claims and the applicable rules of law.
This application claims priority to, and the benefit of, U.S. Provisional Application No. 60/613,808, filed Sep. 28, 2004, for all subject matter common to both applications. The disclosure of said provisional application is hereby incorporated by reference in its entirety. This application also relates to co-pending U.S. patent application Ser. No. 11/237,420, filed concurrently with this application on Sep. 28, 2005.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3556294 | Walck et al. | Jan 1971 | A |
| 3803109 | Nemoto et al. | Apr 1974 | A |
| 3967728 | Gordon et al. | Jul 1976 | A |
| 4308120 | Pennewiss et al. | Dec 1981 | A |
| 4323547 | Knust et al. | Apr 1982 | A |
| 4664114 | Ghodstain | May 1987 | A |
| 4813210 | Masuda et al. | Mar 1989 | A |
| 4814329 | Harsanyi et al. | Mar 1989 | A |
| 4847301 | Murray | Jul 1989 | A |
| 4883667 | Eckenhoff | Nov 1989 | A |
| 4886787 | De Belder et al. | Dec 1989 | A |
| 4894231 | Moreau et al. | Jan 1990 | A |
| 4895724 | Cardinal et al. | Jan 1990 | A |
| 4938763 | Dunn et al. | Jul 1990 | A |
| 4941308 | Grabenkort et al. | Jul 1990 | A |
| 4968302 | Schluter et al. | Nov 1990 | A |
| 5017229 | Burns et al. | May 1991 | A |
| 5147374 | Fernandez | Sep 1992 | A |
| 5151272 | Engstrom et al. | Sep 1992 | A |
| 5171148 | Wasserman et al. | Dec 1992 | A |
| 5179174 | Elton | Jan 1993 | A |
| 5254105 | Haaga | Oct 1993 | A |
| 5356432 | Rutkow et al. | Oct 1994 | A |
| 5368602 | de la Torre | Nov 1994 | A |
| 5371109 | Engstrom et al. | Dec 1994 | A |
| 5380328 | Morgan | Jan 1995 | A |
| 5403283 | Luther | Apr 1995 | A |
| 5447940 | Harvey et al. | Sep 1995 | A |
| 5464650 | Berg et al. | Nov 1995 | A |
| 5480653 | Aguadisch et al. | Jan 1996 | A |
| 5509899 | Fan et al. | Apr 1996 | A |
| 5579149 | Moret et al. | Nov 1996 | A |
| 5580923 | Yeung et al. | Dec 1996 | A |
| 5591230 | Horn et al. | Jan 1997 | A |
| 5612074 | Leach | Mar 1997 | A |
| 5614284 | Kranzler et al. | Mar 1997 | A |
| 5627077 | Dyllick-Brenzinger et al. | May 1997 | A |
| 5637113 | Tartaglia et al. | Jun 1997 | A |
| 5665115 | Cragg | Sep 1997 | A |
| 5695525 | Mulhauser et al. | Dec 1997 | A |
| 5700286 | Tartaglia et al. | Dec 1997 | A |
| 5736152 | Dunn | Apr 1998 | A |
| 5753259 | Engstrom et al. | May 1998 | A |
| 5760081 | Leaf et al. | Jun 1998 | A |
| 5766246 | Mulhauser et al. | Jun 1998 | A |
| 5766710 | Turnlund et al. | Jun 1998 | A |
| 5789465 | Harvey et al. | Aug 1998 | A |
| 5817343 | Burke | Oct 1998 | A |
| 5824082 | Brown | Oct 1998 | A |
| 5837313 | Ding et al. | Nov 1998 | A |
| 5843919 | Burger | Dec 1998 | A |
| 5874470 | Nehne et al. | Feb 1999 | A |
| 5879359 | Dorigatti et al. | Mar 1999 | A |
| 5898040 | Shalaby et al. | Apr 1999 | A |
| 5906831 | Larsson et al. | May 1999 | A |
| 5931165 | Reich et al. | Aug 1999 | A |
| 5955502 | Hansen et al. | Sep 1999 | A |
| 5986043 | Hubbell et al. | Nov 1999 | A |
| 6005004 | Katz et al. | Dec 1999 | A |
| 6010766 | Braun et al. | Jan 2000 | A |
| 6010776 | Exsted et al. | Jan 2000 | A |
| 6015844 | Harvey et al. | Jan 2000 | A |
| 6028164 | Loomis | Feb 2000 | A |
| 6040330 | Hausheer et al. | Mar 2000 | A |
| 6056970 | Greenawalt et al. | May 2000 | A |
| 6077698 | Swan et al. | Jun 2000 | A |
| 6083950 | Anand et al. | Jul 2000 | A |
| 6090809 | Anand et al. | Jul 2000 | A |
| 6117911 | Grainger et al. | Sep 2000 | A |
| 6120789 | Dunn | Sep 2000 | A |
| 6146358 | Rowe | Nov 2000 | A |
| 6152944 | Holman et al. | Nov 2000 | A |
| 6176863 | Kugel et al. | Jan 2001 | B1 |
| 6193746 | Strecker | Feb 2001 | B1 |
| 6197357 | Lawton et al. | Mar 2001 | B1 |
| 6203551 | Wu | Mar 2001 | B1 |
| 6206916 | Furst | Mar 2001 | B1 |
| 6211315 | Larock et al. | Apr 2001 | B1 |
| 6228383 | Hansen et al. | May 2001 | B1 |
| 6229032 | Jacobs et al. | May 2001 | B1 |
| 6245811 | Horrobin et al. | Jun 2001 | B1 |
| 6254634 | Anderson et al. | Jul 2001 | B1 |
| 6262109 | Clark et al. | Jul 2001 | B1 |
| 6273913 | Wright et al. | Aug 2001 | B1 |
| 6284268 | Mishra et al. | Sep 2001 | B1 |
| 6299604 | Ragheb et al. | Oct 2001 | B1 |
| 6326360 | Kanazawa et al. | Dec 2001 | B1 |
| 6331568 | Horrobin | Dec 2001 | B1 |
| 6342254 | Soudant et al. | Jan 2002 | B1 |
| 6346110 | Wu | Feb 2002 | B2 |
| 6358556 | Ding et al. | Mar 2002 | B1 |
| 6364893 | Sahatjian et al. | Apr 2002 | B1 |
| 6368658 | Schwarz et al. | Apr 2002 | B1 |
| 6369039 | Palasis et al. | Apr 2002 | B1 |
| 6387379 | Goldberg et al. | May 2002 | B1 |
| 6410587 | Grainger et al. | Jun 2002 | B1 |
| 6444318 | Guire et al. | Sep 2002 | B1 |
| 6451373 | Hossainy et al. | Sep 2002 | B1 |
| 6465525 | Guire et al. | Oct 2002 | B1 |
| 6471980 | Sirhan et al. | Oct 2002 | B2 |
| 6479683 | Abney et al. | Nov 2002 | B1 |
| 6491938 | Kunz | Dec 2002 | B2 |
| 6503556 | Harish et al. | Jan 2003 | B2 |
| 6525145 | Gevaert et al. | Feb 2003 | B2 |
| 6527801 | Dutta | Mar 2003 | B1 |
| 6534693 | Fischell et al. | Mar 2003 | B2 |
| 6548081 | Sadozai et al. | Apr 2003 | B2 |
| 6565659 | Pacetti et al. | May 2003 | B1 |
| 6569441 | Kunz et al. | May 2003 | B2 |
| 6599323 | Melican et al. | Jul 2003 | B2 |
| 6610035 | Yang et al. | Aug 2003 | B2 |
| 6610068 | Yang et al. | Aug 2003 | B1 |
| 6630151 | Tarletsky et al. | Oct 2003 | B1 |
| 6630167 | Zhang | Oct 2003 | B2 |
| 6632822 | Rickards et al. | Oct 2003 | B1 |
| 6641611 | Jayaraman | Nov 2003 | B2 |
| 6645547 | Shekalim | Nov 2003 | B1 |
| 6663880 | Roorda et al. | Dec 2003 | B1 |
| 6669735 | Pelissier | Dec 2003 | B1 |
| 6670355 | Azrolan et al. | Dec 2003 | B2 |
| 6677342 | Wolff et al. | Jan 2004 | B2 |
| 6677386 | Giezen et al. | Jan 2004 | B1 |
| 6685956 | Chu et al. | Feb 2004 | B2 |
| 6730064 | Ragheb et al. | May 2004 | B2 |
| 6753071 | Pacetti | Jun 2004 | B1 |
| 6761903 | Chen et al. | Jul 2004 | B2 |
| 6764509 | Chinn et al. | Jul 2004 | B2 |
| 6776796 | Falotico et al. | Aug 2004 | B2 |
| 6794485 | Shalaby et al. | Sep 2004 | B2 |
| 6833004 | Ishii et al. | Dec 2004 | B2 |
| 6852330 | Bowman et al. | Feb 2005 | B2 |
| 6875230 | Morita et al. | Apr 2005 | B1 |
| 6884428 | Binette et al. | Apr 2005 | B2 |
| 6887270 | Miller et al. | May 2005 | B2 |
| 6899729 | Cox et al. | May 2005 | B1 |
| 6918927 | Bates et al. | Jul 2005 | B2 |
| 6996952 | Gupta et al. | Feb 2006 | B2 |
| 7070858 | Shalaby et al. | Jul 2006 | B2 |
| 7101381 | Ford et al. | Sep 2006 | B2 |
| 7152611 | Brown et al. | Dec 2006 | B2 |
| 7415811 | Gottlieb et al. | Aug 2008 | B2 |
| 8124127 | Faucher et al. | Feb 2012 | B2 |
| 8263102 | Labrecque et al. | Sep 2012 | B2 |
| 8367099 | Herweck et al. | Feb 2013 | B2 |
| 8501229 | Faucher et al. | Aug 2013 | B2 |
| 8722077 | Labrecque et al. | May 2014 | B2 |
| 20010025034 | Arbiser | Sep 2001 | A1 |
| 20010025196 | Chinn et al. | Sep 2001 | A1 |
| 20010051595 | Lyons et al. | Dec 2001 | A1 |
| 20020002154 | Guivarc'h et al. | Jan 2002 | A1 |
| 20020007209 | Scheerder et al. | Jan 2002 | A1 |
| 20020012741 | Heinz et al. | Jan 2002 | A1 |
| 20020032414 | Ragheb et al. | Mar 2002 | A1 |
| 20020055701 | Fischell et al. | May 2002 | A1 |
| 20020098278 | Bates et al. | Jul 2002 | A1 |
| 20020116045 | Eidenschink | Aug 2002 | A1 |
| 20020120333 | Keogh et al. | Aug 2002 | A1 |
| 20020122877 | Harish et al. | Sep 2002 | A1 |
| 20020142089 | Koike et al. | Oct 2002 | A1 |
| 20020193829 | Kennedy et al. | Dec 2002 | A1 |
| 20030003125 | Nathan et al. | Jan 2003 | A1 |
| 20030004564 | Elkins et al. | Jan 2003 | A1 |
| 20030055403 | Nestenborg et al. | Mar 2003 | A1 |
| 20030065292 | Darouiche et al. | Apr 2003 | A1 |
| 20030065345 | Weadock | Apr 2003 | A1 |
| 20030069632 | De Scheerder et al. | Apr 2003 | A1 |
| 20030072784 | Williams | Apr 2003 | A1 |
| 20030077272 | Pathak | Apr 2003 | A1 |
| 20030083740 | Pathak | May 2003 | A1 |
| 20030086958 | Arnold et al. | May 2003 | A1 |
| 20030094728 | Tayebi | May 2003 | A1 |
| 20030108588 | Chen et al. | Jun 2003 | A1 |
| 20030130206 | Koziak et al. | Jul 2003 | A1 |
| 20030152609 | Fischell et al. | Aug 2003 | A1 |
| 20030175408 | Timm et al. | Sep 2003 | A1 |
| 20030176915 | Wright et al. | Sep 2003 | A1 |
| 20030181975 | Ishii et al. | Sep 2003 | A1 |
| 20030191179 | Joshi-Hangal et al. | Oct 2003 | A1 |
| 20030204168 | Bosma et al. | Oct 2003 | A1 |
| 20030204618 | Foster et al. | Oct 2003 | A1 |
| 20030207019 | Shekalim et al. | Nov 2003 | A1 |
| 20040006296 | Fischell et al. | Jan 2004 | A1 |
| 20040014810 | Horrobin | Jan 2004 | A1 |
| 20040018228 | Fischell et al. | Jan 2004 | A1 |
| 20040039441 | Rowland et al. | Feb 2004 | A1 |
| 20040071756 | Fischell et al. | Apr 2004 | A1 |
| 20040073284 | Bates et al. | Apr 2004 | A1 |
| 20040117007 | Whitbourne et al. | Jun 2004 | A1 |
| 20040133275 | Mansmann | Jul 2004 | A1 |
| 20040137066 | Jayaraman | Jul 2004 | A1 |
| 20040137179 | Matsuda et al. | Jul 2004 | A1 |
| 20040142094 | Narayanan | Jul 2004 | A1 |
| 20040156879 | Muratoglu et al. | Aug 2004 | A1 |
| 20040161464 | Domb | Aug 2004 | A1 |
| 20040167572 | Roth et al. | Aug 2004 | A1 |
| 20040170685 | Carpenter et al. | Sep 2004 | A1 |
| 20040192643 | Pressato et al. | Sep 2004 | A1 |
| 20040215219 | Eldridge et al. | Oct 2004 | A1 |
| 20040230176 | Shanahan et al. | Nov 2004 | A1 |
| 20040256264 | Israelsson et al. | Dec 2004 | A1 |
| 20050010078 | Jamiolkowski et al. | Jan 2005 | A1 |
| 20050084514 | Shebuski et al. | Apr 2005 | A1 |
| 20050095267 | Campbell et al. | May 2005 | A1 |
| 20050106209 | Ameri et al. | May 2005 | A1 |
| 20050112170 | Hossainy et al. | May 2005 | A1 |
| 20050113849 | Popadiuk et al. | May 2005 | A1 |
| 20050158361 | Dhondt et al. | Jul 2005 | A1 |
| 20050159809 | Hezi-Yamit et al. | Jul 2005 | A1 |
| 20050182485 | Falotico et al. | Aug 2005 | A1 |
| 20050187376 | Pacetti | Aug 2005 | A1 |
| 20050232971 | Hossainy et al. | Oct 2005 | A1 |
| 20050249775 | Falotico et al. | Nov 2005 | A1 |
| 20050283229 | Dugan et al. | Dec 2005 | A1 |
| 20060008501 | Dhont et al. | Jan 2006 | A1 |
| 20060036311 | Nakayama et al. | Feb 2006 | A1 |
| 20060058881 | Trieu | Mar 2006 | A1 |
| 20060067976 | Ferraro et al. | Mar 2006 | A1 |
| 20060067977 | Labrecque et al. | Mar 2006 | A1 |
| 20060068674 | Dixit et al. | Mar 2006 | A1 |
| 20060083768 | Labrecque et al. | Apr 2006 | A1 |
| 20060093643 | Stenzel | May 2006 | A1 |
| 20060110457 | Labrecque et al. | May 2006 | A1 |
| 20060121081 | Labrecque et al. | Jun 2006 | A1 |
| 20060124056 | Behnisch et al. | Jun 2006 | A1 |
| 20060134209 | Labhasetwar et al. | Jun 2006 | A1 |
| 20060158361 | Chou | Jul 2006 | A1 |
| 20060204738 | Dubrow et al. | Sep 2006 | A1 |
| 20060210701 | Chappa et al. | Sep 2006 | A1 |
| 20060240069 | Utas et al. | Oct 2006 | A1 |
| 20060246105 | Molz et al. | Nov 2006 | A1 |
| 20070084144 | Labrecque et al. | Apr 2007 | A1 |
| 20070093894 | Darouiche | Apr 2007 | A1 |
| 20070141112 | Falotico et al. | Jun 2007 | A1 |
| 20070212411 | Fawzy et al. | Sep 2007 | A1 |
| 20070280986 | Gil et al. | Dec 2007 | A1 |
| 20070286891 | Kettlewell et al. | Dec 2007 | A1 |
| 20070299538 | Roeber | Dec 2007 | A1 |
| 20080038307 | Hoffmann | Feb 2008 | A1 |
| 20080044481 | Harel | Feb 2008 | A1 |
| 20080086216 | Wilson et al. | Apr 2008 | A1 |
| 20080118550 | Martakos et al. | May 2008 | A1 |
| 20080206305 | Herweck et al. | Aug 2008 | A1 |
| 20080279929 | Devane et al. | Nov 2008 | A1 |
| 20080286440 | Scheer | Nov 2008 | A1 |
| 20090011116 | Herweck et al. | Jan 2009 | A1 |
| 20090047414 | Corbeil et al. | Feb 2009 | A1 |
| 20100183697 | Swanick et al. | Jul 2010 | A1 |
| 20100209473 | Dhont et al. | Aug 2010 | A1 |
| 20100233232 | Swanick et al. | Sep 2010 | A1 |
| 20120016038 | Faucher et al. | Jan 2012 | A1 |
| Number | Date | Country |
|---|---|---|
| 0471566 | Feb 1992 | EP |
| 0610731 | Aug 1994 | EP |
| 0623354 | Nov 1994 | EP |
| 0730864 | Sep 1996 | EP |
| 0790822 | Aug 1997 | EP |
| 0873133 | Oct 1998 | EP |
| 0917561 | May 1999 | EP |
| 1140243 | Oct 2001 | EP |
| 1181943 | Feb 2002 | EP |
| 1270024 | Jan 2003 | EP |
| 1273314 | Jan 2003 | EP |
| 1364628 | Nov 2003 | EP |
| 1520795 | Apr 2005 | EP |
| 1557183 | Jul 2005 | EP |
| 2083875 | Aug 2009 | EP |
| 1402906 | Jun 2011 | EP |
| 20080025986 | Mar 2008 | KR |
| WO 8600912 | Jul 1984 | WO |
| WO 9001969 | Mar 1990 | WO |
| WO 9526715 | Oct 1995 | WO |
| WO 9702042 | Jan 1997 | WO |
| WO 9709367 | Mar 1997 | WO |
| WO 9713528 | Apr 1997 | WO |
| WO 9830206 | Jul 1998 | WO |
| WO 9854275 | Dec 1998 | WO |
| WO 9925336 | May 1999 | WO |
| WO-0040278 | Jul 2000 | WO |
| WO-0062830 | Oct 2000 | WO |
| WO 0124866 | Apr 2001 | WO |
| WO 0126585 | Apr 2001 | WO |
| WO 0137808 | May 2001 | WO |
| WO 0160586 | Aug 2001 | WO |
| WO 0166036 | Sep 2001 | WO |
| WO 0176649 | Oct 2001 | WO |
| WO 0249535 | Jun 2002 | WO |
| WO-02100455 | Dec 2002 | WO |
| WO-03000308 | Jan 2003 | WO |
| WO 03015748 | Feb 2003 | WO |
| WO 03028622 | Apr 2003 | WO |
| WO 03037397 | May 2003 | WO |
| WO 03037398 | May 2003 | WO |
| WO 03039612 | May 2003 | WO |
| WO 03041756 | May 2003 | WO |
| WO 03039612 | May 2003 | WO |
| WO 03070125 | Aug 2003 | WO |
| WO 03092741 | Nov 2003 | WO |
| WO 03092779 | Nov 2003 | WO |
| WO 2004004598 | Jan 2004 | WO |
| WO 2004006976 | Jan 2004 | WO |
| WO 2004006978 | Jan 2004 | WO |
| WO 2004028583 | Apr 2004 | WO |
| WO 2004091684 | Oct 2004 | WO |
| WO 2005000165 | Jan 2005 | WO |
| WO 2005016400 | Feb 2005 | WO |
| WO 2005053767 | Jun 2005 | WO |
| WO 2005073091 | Aug 2005 | WO |
| WO 2005116118 | Dec 2005 | WO |
| WO 2006024488 | Mar 2006 | WO |
| WO 2006036967 | Apr 2006 | WO |
| WO 2006102374 | Sep 2006 | WO |
| WO 2007047028 | Apr 2007 | WO |
| WO 2008057328 | May 2008 | WO |
| WO 2012009707 | Jan 2012 | WO |
| Entry |
|---|
| Websters Dictionary Online, Accessed on Feb. 13, 2009, entry for “polymer” p. 1 of 1. |
| “polymerization” Merriam-Webster Online Dictionary, retrieved from <www.merriam-webster.com> on Dec. 13, 2009; Merriam-Webster's Inc. 2009; pp. 1. |
| Shahidi, Fereidoon ed.; “Bailey's Industrial Oil and Fat Products” 2005; John Wiley and Sons; vol. 5, Edible Oil and Fat Products: Processing Technologies, pp. 1-15. |
| Sweetman, Sean C; “Martindale: The complete drug reference,” 33rd ed., 2002, Pharmaceutical Press; pp. 1-90. |
| Drugs.com “Drug Index A to Z”, retrieved from <www.drugs.com> on Apr. 1, 2013; pp. 1-4. |
| Garner, Brian A.; “A Dictionary of Modern Legal Usage,” Second ed. 1987; pp. 389-390; and 713-717. |
| Pearlman, Daniel D & Paula R.; “Guide to Rapid Revision,” 3rd ed. 1982; Bobbs-Merril Educational Publishing; pp. 25-27. |
| Canter, Sheryl; “Chemistry of Cast Iron Seasoning: A Science-Based How-To”, retrieved from <sherylcanter.com> on Apr. 5, 2013; pp. 1-5, as provided. |
| O'Neil, Maryadelle J. et al.; “The Merck Index—An Encyclopedia of Chemicals, Drugs, and Biologicals, 14th ed.” 2006; entries for “Calcium Carbonate,” “Cyclosporins,” “Prussian Blue,” and “Rapamycin”, pp. 1-12, as provided. |
| Nagao et al.; “Conjugated Fatty Acids in Food and Their Health Benefits,” 2005, The Society for Biotechnology, Japan; Journal of Bioscience and Bioengineering, vol. 100, No. 2, pp. 152-157. |
| Goodnight et al.; “Polyunsaturated Fatty Acids, Hyperlipidemia, and Thrombosis,” 1982, American Heart Association; Journal of the American Heart Association, vol. 2, No. 2, pp. 87-113. |
| Drugs.com “Drug Index A to Z”, retrieved from on Apr. 1, 2013; pp. 1-4. |
| Sweetman, Sean C; “Martindale: The complete drug reference,” 33rd ed., 2002, Pharmaceutical Press; pp. 1-90. |
| Andres, Vicente & Castro, Claudia; “Antiproliferative Strategies for the Treatment of Vascular Proliferative Disease,” 2003, Bentham Science Pubs.; Current Vascular Pharamacology, vol. 1, No. 1, pp. 85-98. |
| International Search Report for Application No. PCT/US05/34941, dated May 4, 2006. |
| A paper entitled, “Evaluation of the Biocompatibility and Drug Delivery Capabilities of Biological Oil Based Stent Coatings,” by Li, Shengqiao of the Katholieke Universiteit Leuven. |
| Ahuja et al., “Prevention of Postoperative Intraperitoneal Adhesions—An Experimental Study in Rats”, Journal of Indian Pediatric Surgery , 7:15-20 (2002). |
| Jonasson, Lena et al., “Cyclosporon A inhibits smooth muscle proliferation in the vascular response to injury,” Proc. Natl. Acad. Sci. USA, vol. 85: 2303-2306 (1988). |
| Ogunniyi, D.S., “Castor oil: A vital industrial raw material,” Biosource Technology, vol. 97: 1086-1091 (2006). |
| Redman, L.V. et al., “The drying rate of raw paint oils—a comparison,” The Journal of Industrial and Engineering Chemistry, vol. 5: 630-636 (1913). |
| Jorge, N., “Grasas y Aceites”, 48(1): 17-24, (1997). |
| International Search Report for PCT/US2011/44292, dated Dec. 6, 2011. |
| International Search Report for International Application PCT/US05/034941, dated May 4, 2006. |
| Supplementary European Search Report for EP12004057, dated Apr. 10, 2013. |
| Advisory Action for U.S. Appl. 12/581,582 (listed on SB-08 as U.S. Publication No. 20100183697), dated Nov. 14, 2012. |
| Notice of Allowance for U.S. Appl. No. 11/525,390 (listed on SB-08 as U.S. Publication No. US-2007-0071798), dated Nov. 20, 2012. |
| Non-Final Office Action for U.S. Appl. No. 13/404,487 (listed on SB-08 as US 20120213839), dated Dec. 20, 2012. |
| Non-Final Office Action for U.S. Appl. No. 13/184,512 (listed on SB-08 as 2012-0016038), dated Jan. 31, 2013. |
| Non-Final Office Action for U.S. Appl. No. 11/978,840 (listed on SB-08 as U.S. Publication No. US-2008-0118550, dated Feb. 19, 2013. |
| Non-Final Office Action for U.S. Appl. No. 13/682,991 (listed on SB-08 as U.S. Publication No. US- 2013-0074452), dated Mar. 18, 2013. |
| Notice of Allowance for U.S. Appl. No. 13/404,487 (listed on SB-08 as U.S. Publication No. US- 2012-0213839), dated Apr. 2, 2013. |
| Non-Final Office Action for U.S. Appl. No. 11/236,943 (listed on SB-08 as U.S. Publication No. US- 2006-0067975), dated Apr. 22, 2013. |
| Final Office Action for U.S. Appl. No. 13/184,512 (listed on SB-08 as U.S. Publication No. U.S. 2012-0016038), date Jun. 25, 2013. |
| Non-Final Office Action for U.S. Appl. No. 11/237,264 (listed on SB-08 as U.S. Publication No. US-2006-0067983), dated Jul. 3, 2013. |
| Non-Final Office Action for U.S. Appl. No. 13/593,656 (listed on SB-08 as U.S. Publication No. US-2012-03115219), dated Jul. 15, 2013. |
| Notice of Allowance for U.S. Appl. No. 13/682,991 (listed on SB-08 as U.S. Publication No. US 2013-0074452), dated Aug. 1, 2013. |
| Notice of Allowance for U.S. Appl. No. 11/978,840 (listed on SB-08 as U.S. Publication No. US-2008-0118550), dated Aug. 6, 2013. |
| International Search Report for International Application PCT/US2013/044653, dated Sep. 4, 2013. |
| Mallegol, “Long-Term Behavior of Oil-Based Varnishes and Paints Photo-and Thermooxidation of Cured Linseed Oil”, Journal of the American Oil Chemists' Society, 77:257-263 (2000). |
| Non-Final Office Action for U.S. Appl. No. 11/237,420 (listed on SB-08 as U.S. Publication No. US-2006-0078586), dated Nov. 12, 2013. |
| Non-Final Office Action for U.S. Appl. No. 12/075,223 (listed on SB-08 as U.S. Publication No. US-2008-0206305), dated Nov. 12, 2013. |
| Non-Final Office Action for U.S. Appl. No. 11/980,155 (listed on SB-08 as U.S. Publication No. US-2008-0113001), dated Nov. 12, 2013. |
| Notice of Allowance for U.S. Appl. No. 13/593,656 (listed on SB-08 as U.S. Publication 2012-03115219), dated Jan. 24, 2014. |
| Final Office Action for U.S. Appl. No. 11/237,264 (listed on SB-08 as U.S. Publication No. US-2006-0067983), dated Dec. 17, 2013. |
| Autosuture, “ParietexTM Composite OS Series Mesh,” retrieved online at http://www.autosuture.com/AutoSuture/pagebuilder.aspx?topicID=135734&breadcrumbs=135601:0 (2007). |
| Binder et al., “Chromatographic Analysis of Seed Oils. Fatty Acid Composition of Castor Oil,” The Journal of the American Oil Chemists' Society, vol. 39:513-517 (1962). |
| Camurus, “In our endeavors to create the unique, we start with the best. Your product.”. |
| CECW-EE, “Ch. 4: Coating Types and Characteristics,” Engineering and Design—Painting: New Construction and Maintenance, pp. 4-1 to 4-24 (1995). |
| De Scheerder, Ivan K., et al. “Biocompatibility of polymer-coated oversized metallic stents implanted in normal porcine coronary arteries,” Atherosclerosis, vol. 114:105-114. (1995). |
| Drummond, Calum J., et al., “Surfactant self-assembly objects as novel drug delivery vehicles,” Current Opinion in Colliod & Interface Science, vol. 4:449-456 (2000). |
| Engstrom, Sven, “Drug Delivery from Cubic and Other Lipid-water Phases,” Lipid Technology, vol. 2(2):42-45 (1990). |
| Guler, et al. “Some empirical equations for oxopolymerization of linseed oil,” Progress in Organic Coatings, vol. 51:365-371 (2004). |
| Hwang, Chao-Wei, et al, “Physiological Transport Forces Govern Drug Distribution for Stent-Based Delivery,” Circulation, vol. 104:600-605 (2001). |
| Mallegol, et al., “Drier Influence on the Curing of Linseed Oil,” Progress in Organic Coatings 39:107-113 (2000). |
| Morse, Richard “Molecular Distillation of Polymerized Drying Oils,” Industrial and Engineering Chemisry 33:1039-1043 (1941). |
| Oberhoff, Martin, et al, “Local and Systemic Delivery of Low Molecular Weight Heparin Following PTCA: Acute Results and 6-Month Follow-Up of the Initial Clinical Experience With the Porous Balloon (PILOT-Study),” Catheterization and Cardiovascular Diagnosis, vol. 44:267-274 (1998). |
| Salu, Koen J., et al, “Addition of cytochalasin D to a biocompatible oil stent coating inhibits intimal hyperplasia in a porcine coronary model,” Coronary Artery Disease, vol. 14(8):545-555 (2003). |
| Scheller, Bruno, et al, “Addition of Paclitaxel to Contrast Media Prevents Restenosis After Coronary Stent Implantation,” Journal of the American College of Cardiology, vol. 42(8):1415-1420 (2003). |
| Van der Giessen, Willem J., et al, “Marked Inflammatory Sequelae to Implantation of Biodegradable and Nonbiodegradable Polymers in Porcine Coronary Arteries,” Circulation, vol. 94:1690-1697 (1996). |
| Wikipedia, “Sirolimus,” pp. 1-13, available online at http://en.wikipedia.org/wiki/Sirolimus, date accessed May 11, 2011. |
| Crivello et al., “Epoxidized triglycerides as renewable monomers in photoinitiated cationic polymerization,” Chem. Mater, 1992:692-699. |
| Encylopedia Britannica Online, “Surface Coating,” available online at http://www.britannica.com/EBchecked/topic/575029/surface-coating>, date accessed Jun. 17, 2011. |
| Timir-Balizsy et al., “Chemical Principals of Textile Conservation,” Oxford: Elsevier Science Ltd., 1998:117-119. |
| International Search Report for International Application PCT/US05/034601, dated Apr. 10, 2006. |
| International Search Report for International Application PCT/US05/034610, dated Mar. 16, 2006. |
| International Search Report for International Application PCT/US05/034614, dated Aug. 29, 2006. |
| International Search Report for International Application PCT/US05/034615, dated May 16, 2006. |
| International Search Report for International Application PCT/US05/034678, dated Aug. 28, 2006. |
| International Search Report for International Application PCT/US05/034681, dated Jul. 26, 2006. |
| International Search Report for International Application PCT/US05/034682, dated Jul. 20, 2006. |
| International Search Report for International Application PCT/US05/034836, dated Jul. 6, 2006. |
| International Search Report for International Application PCT/US06/037184, dated Feb. 22, 2007. |
| International Preliminary Report on Patentability for International Application PCT/US06/040753, dated Oct. 3, 2008. |
| International Search Report for International Application PCT/US06/040753, dated Sep. 24, 2007. |
| International Search Report for International Application PCT/US07/019978, dated May 7, 2009. |
| International Search Report for International Application PCT/US07/022860, dated Apr. 22, 2009. |
| International Search Report for International Application PCT/US07/022944, dated Apr. 8, 2009. |
| International Search Report for International Application PCT/US08/000565, dated May 4, 2009. |
| International Preliminary Examination Report for International Application PCT/US08/071547, dated Aug. 26, 2010. |
| International Search Report for International Application PCT/US08/071547, dated Oct. 22, 2008. |
| International Preliminary Report on Patentability for International Application PCT/US08/071565, dated Aug. 27, 2009. |
| International Search Report for International Application PCT/US08/071565, dated Nov. 10, 2008. |
| International Search Report for International Application PCT/US08/085386, dated Feb. 4, 2009. |
| International Search Report for International Application PCT/US09/037364, dated Aug. 27, 2009. |
| International Search Report for International Application PCT/US10/026521, dated Jun. 23, 2010. |
| International Search Report for International Application PCT/US10/052899, dated Jan. 10, 2011. |
| Supplementary European Search Report for Application No. EP 05 80 2894, dated Jul. 27, 2011. |
| Supplementary European Search Report in Application No. 05 800 844, dated Aug. 19, 2011. |
| Supplementary European Search Report in Application No. EP 05 80 4291, dated Jul. 26, 2011. |
| Supplementary European Search Report in Application No. EP 05 85 8430, dated Aug. 18, 2011. |
| Supplementary European Search Report for Application No. EP 08877338.7, dated Aug. 16, 2012. |
| Supplementary European Search Report for Application No. EP09819594.4, dated Aug. 14, 2012. |
| Non-final Office Action for U.S. Appl. No. 11/236,908 (listed on SB/08 as US 2006/0067974), mailed Mar. 25, 2006. |
| Final Office Action for U.S. Appl. No. 11/236,908 (listed on SB/08 as US 2006/0067974), mailed May 17, 2011. |
| Non-final Office Action for U.S. Appl. No. 11/236,908 (listed on SB/08 as US 2006/0067974), mailed Aug. 24, 2009. |
| Non-final Office Action for U.S. Appl. No. 11/236,977 (listed on SB/08 as US 2006/0088596), mailed Aug. 3, 2009. |
| Final Office Action for U.S. Appl. No. 11/237,263 (listed on SB/08 as US 2006/0110457), mailed Jul. 7, 2010. |
| Non-final Office Action for U.S. Appl. No. 11/237,263 (listed on SB/08 as US 2006/0110457), mailed Oct. 7, 2009. |
| Final Office Action for U.S. Appl. No. 11/237,264 (listed on SB/08 as US 2006/0067983), mailed Jun. 2, 2010. |
| Non-final Office Action for U.S. Appl. No. 11/237,264 (listed on SB/08 as US 2006/0067983), mailed Oct. 5, 2009. |
| Final Office Action for U.S. Appl. No. 11/701,799 (listed on SB/08 as US 2008/0109017), mailed Nov. 23, 2010. |
| Non-final Office Action for U.S. Appl. No. 11/237,420 (listed on SB/08 as US 2006/0078586), mailed Mar. 5, 2009. |
| Final Office Action for U.S. Appl. No. 11/237,420 (listed on SB/08 as US 2006/0078586), mailed Nov. 4, 2009. |
| Non-final Office Action for U.S. Appl. No. 11/237,420 (listed on SB/08 as US 2006/0078586), mailed Dec. 6, 2010. |
| Non-final Office Action for U.S. Appl. No. 11/238,532 (listed on SB/08 as US 2006/0067976), mailed Mar. 30, 2009. |
| Final Office Action for U.S. Appl. No. 11/238,532 (listed on SB/08 as US 2006/0067976), mailed Sep. 9, 2009. |
| Final Office Action for U.S. Appl. No. 11/238,554 (listed on SB/08 as US 2006/0121081), mailed May 12, 2010. |
| Non-final Office Action for U.S. Appl. No. 11/238,554 (listed on SB/08 as US 2006/0121081), mailed Oct. 9, 2009. |
| Final Office Action for U.S. Appl. No. 11/238,554 (listed on SB/08 as US 2006/0121081), mailed May 1, 2009. |
| Non-final Office Action for U.S. Appl. No. 11/238,554 (listed on SB/08 as US 2006/0121081), mailed Jul. 25, 2008. |
| Non-final Office Action for U.S. Appl. No. 11/238,564 (listed on SB/08 as US 2006/0083768), mailed Apr. 16, 2008. |
| Final Office Action for U.S. Appl. No. 11/238,564 (listed on SB/08 as US 2006/0083768), mailed Aug. 6, 2009. |
| Non-final Office Action for U.S. Appl. No. 11/239,555 (listed on SB/08 as US 2006/0067977), mailed Mar. 30, 2009. |
| Non-final Office Action for U.S. Appl. No. 11/525,328 (listed on SB/08 as US 2007/0084144), mailed Apr. 30, 2007. |
| Non-final Office Action for U.S. Appl. No. 11/525,390 (listed on SB/08 as US 2007/0071798), mailed Jul. 14, 2010. |
| Final Office Action for U.S. Appl. No. 11/525,390 (listed on SB/08 as US 2007/0071798), mailed Feb. 21, 2011. |
| Final Office Action for U.S. Appl. No. 11/582,135 (listed on SB/08 as US 2007/0202149), mailed May 12, 2011. |
| Non-final Office Action for U.S. Appl. No. 11/582,135 (listed on SB/08 as US 2007/0202149), mailed Nov. 9, 2010. |
| Non-final Office Action for U.S. Appl. No. 11/582,135 (listed on SB/08 as US 2007/0202149), mailed Jan. 6, 2010. |
| Non-final Office Action for U.S. Appl. No. 11/582,135 (listed on SB/08 as US 2007/0202149), mailed May 12, 2009. |
| Non-final Office Action for U.S. Appl. No. 11/701,799 (listed on SB/08 as US 2008/0109017), mailed Apr. 12, 2010. |
| Non-final Office Action for U.S. Appl. No. 11/978,840 (listed on SB/08 as US 2008/0118550), mailed Dec. 3, 2010. |
| Non-final Office Action for U.S. Appl. No. 11/980,155 (listed on SB/08 as US 2008/0113001), mailed Mar. 24, 2011. |
| Non-final Office Action for U.S. Appl. No. 12/075,223 (listed on SB/08 as US 2008/0206305), mailed Dec. 8, 2010. |
| Non-final Office Action for U.S. Appl. No. 12/325,546 (listed on SB/08 as US 2009/0181937), mailed Feb. 25, 2010. |
| Final Office Action for U.S. Appl. No. 12/325,546 (listed on SB/08 as US 2009/0181937), mailed Aug. 31, 2010. |
| Non-final Office Action for U.S. Appl. No. 12/364,763 (listed on SB/08 as US 2009/0208552), mailed Dec. 11, 2009. |
| Final Office Action for U.S. Appl. No. 12/364,763 (listed on SB/08 as US 2009/0208552), mailed Sep. 21, 2010. |
| Interview summary for U.S. Appl. No. 11/236,908 (listed on SB/08 as US 2006/0067974), mailed May 5, 2009. |
| Interview summary for U.S. Appl. No. 11/236,908 (listed on SB/08 as US 2006/0067974), mailed Dec. 2, 2010. |
| Interview summary for U.S. Appl. No. 11/237,420 (listed on SB/08 as US 2006/0078586), mailed May 5, 2009. |
| Interview summary for U.S. Appl. No. 11/582,135 (listed on SB/08 as US 2007/0202149), mailed Dec. 7, 2010. |
| Interview summary for U.S. Appl. No. 12/325,546 (listed on SB/08 as US 2009/0181937), mailed Dec. 2, 2010. |
| Interview summary for U.S. Appl. No. 12/364,763 (listed on SB/08 as US 2009/0208552), mailed Dec. 2, 2010. |
| Final Office Action for U.S. Appl. No. 11/237,420 (listed on SB/08 as US 2006/0078586), mailed Jul. 13, 2011. |
| Final Office Action for U.S. Appl. No. 11/978,840 (listed on SB/08 as US 2008/0118550), mailed Jun. 22, 2011. |
| Final Office Action for U.S. Appl. No. 12/075,223 (listed on SB/08 as US 2008/0206305), mailed Aug. 11, 2011. |
| Non-final Office Action for U.S. Appl. No. 11/525,390 (listed on SB/08 as US 2007/0071798), mailed Jul. 11, 2011. |
| Non-Final Office Action for U.S. Appl. No. 11/701,799 (listed on SB/08 as US 2008/0109017), mailed Aug. 17, 2011. |
| Non-Final Office Action for U.S. Appl. No. 11/582,135 (listed on SB/08 as US-2007-0202149), mailed Oct. 14, 2011. |
| Final Office Action for U.S. Appl. No. 11/980,155 (listed on SB/08 as US-2008-0113001), mailed Oct. 21, 2011. |
| Non-Final Office Action for U.S. Appl. No. 11/236,908 (listed on SB/08 as US-2006-0067974), mailed Dec. 2, 2011. |
| Non-Final Office Action for U.S Appl. No. 12/182,261 (listed on SB/08 as US 2009-0047414), mailed Dec. 21, 2011. |
| Non-Final Office Action for U.S. Appl. No. 12/401,243 (listed on SB/08 as US 2010-0233232), mailed Jan. 5, 2012. |
| Notice of Allowance for U.S. Appl. No. 11/582,135 (listed on SB/08 as US 2007-0202149), mailed Jan. 9, 2012. |
| Non-Final Office Action for U.S. Appl. No. 12/182,165 (listed on SB/08 as US 2009-0011116), mailed Jan. 5, 2012. |
| Final Office Action for U.S. Appl. No. 11/701,799 (listed on SB/08 as US 2008/0109017), mailed Feb. 13, 2012. |
| Non-Final Office Action for U.S. Appl. No. 12/581,582 (listed on SB/08 as US 20100183697), mailed Mar. 14, 2012. |
| Final Office Action for U.S. Appl. No. 12/182,165 (listed on SB/08 as US 2009-0011116), mailed Apr. 6, 2012. |
| Final Office Action for U.S. Appl. No. 12/182,261 (listed on SB-08 as US 2009/0047414), mailed Apr. 30, 2012. |
| Notice of Allowance for U.S. Appl. No. 11/236,908 (listed on SB/08 as US-2006-0067974), mailed May 11, 2012. |
| Final Office Action for U.S. Appl. No. 12/401,243 (listed on SB/08 as US-2010-0233232), mailed Jun. 11, 2012. |
| Notice of Allowance for U.S. Appl. No. 12/182,261 (listed on SB/08 as US US-20090047414), mailed Jul. 23, 2012. |
| Advisory Action for U.S. Appl. No. 12/401,243 (listed on SB/08 as US 2010-0233232), mailed Aug. 27, 2012. |
| Final Office Action for U.S. Appl. No. 12/581,582 (listed on SB-08 as US 2010/0183697), mailed Aug. 29, 2012. |
| Notice of Allowance for U.S. Appl. No. 11/525390 (listed on SB/08 as US-2007/0071798), mailed Oct. 4, 2012. |
| Notice of Allowance for U.S. Appl. No. 11/237,264 (listed on SB-08 as U.S. Publication No. US-2006-0067983), dated Mar. 27, 2014. |
| Notice of Allowance for U.S. Appl. No. 11/237,263 (listed on SB-08 as U.S. Publication No. US-US-2006-0110457), dated Mar. 27, 2014. |
| Uchida, et al., “Swelling Process and Order-Disorder Transition of Hydrogel Containing Hydrophobic Ionizable Groups”, Macromolecules, 28, 4583-4586 (1995). |
| Gutfinger, et al., “Polyphenols in Olive Oils”, Journal of the American Oil Chemists Society, 58(11): 966-968 (1981). |
| Portilla, et al., “Prevention of Peritoneal Adhesions by Intraperitoneal Administration of Vitamin E: An Experimental Study in Rats”, Diseases of the Colon and Rectum,, 47; 2157-2162 (2005). |
| Sano, et al., “A controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease”, The New England Journal of Medicine, 336; 1216-1222 (1997). |
| Non Final Office Action for U.S. Appl. No. 12/581,582 (listed on SB-08 as U.S. Publication 2010-0183697), dated May 29, 2014. |
| Non-Final Office Action for U.S. Appl. No. 13/943,489, dated Jul. 1, 2014. |
| Final Office Action for U.S. Appl. No. 11/980,155, dated Jul. 21, 2014. |
| Final Office Action for U.S. Appl. No. 11/237,420, dated Jul. 22, 2014. |
| Non-Final Office Action for U.S. Appl. No. 11/701,799, dated Jul. 22, 2014. |
| Final Office Action for U.S. Appl. No. 12/075,223, dated Jul. 22, 2014. |
| Supplementary European Search Report for Application No. EP 10825447, dated Mar. 31, 2014. |
| Non Final Office Action for U.S. Appl. No. 12/325,546 (listed on SB-08 as U.S. Publication No. US-2009-0181937), dated Apr. 22, 2014. |
| Non Final Office Action for U.S. Appl. No. 12/364,763 (listed on SB-08 as U.S. Publication No. US-2009-0208552), dated Apr. 23, 2014. |
| Non Final Office Action for U.S. Appl. No. 12/401,243 (listed on SB/08 as US 20100233232), mailed May 8, 2014. |
| Non-Final Office Action for U.S. Appl. No. 13/843,068, dated Sep. 29, 2014. |
| Non-Final Office Action for U.S. Appl. No. 13/184,512, dated Oct. 10, 2014. |
| Non-Final Office Action for U.S. Appl. No. 12/075,223, dated Oct. 29, 2014. |
| Non-Final Office Action for U.S. Appl. No. 11/980,155, dated Nov. 7, 2014. |
| Notice of Allowance for U.S. Appl. No. 12/364,763, dated Dec. 5, 2014. |
| Notice of Allowance for U.S. Appl. No. 12/325,546, dated Dec. 8, 2014. |
| Number | Date | Country | |
|---|---|---|---|
| 20060067975 A1 | Mar 2006 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60613808 | Sep 2004 | US |
